Get the Stockscreener App
5.4123
0.48%
-0.0277
Ardelyx Inc stock is traded at $5.4123, with a volume of 406.06K.
It is down -0.48% in the last 24 hours and down -4.35% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.44
Open:
$5.38
24h Volume:
406.06K
Relative Volume:
0.10
Market Cap:
$1.28B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-17.27
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
+1.76%
1M Performance:
-4.35%
6M Performance:
-14.20%
1Y Performance:
-37.34%
1-Day Range:
$5.37
$5.58
1-Week Range:
$5.16
$5.73
52-Week Range:
$4.32
$9.33
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.415 | 1.28B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.93 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.47 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.49 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.97 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com South Africa
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns “Buy” Rating from LADENBURG THALM/SH SH - Defense World
Ardelyx CEO Michael Raab sells $223,198 in stock - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential By Investing.com - Investing.com Australia
Ardelyx, Inc. to Host Earnings Call - ACCESS Newswire
Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings - Defense World
Ardelyx (NASDAQ:ARDX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
Rhumbline Advisers Purchases 6,070 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx (NASDAQ:ARDX) Coverage Initiated by Analysts at BTIG Research - Defense World
BTIG sets Ardelyx stock Buy rating, $14 price target - Investing.com India
BTIG sets Ardelyx stock Buy rating, $14 price target By Investing.com - Investing.com South Africa
BTIG Initiates Ardelyx at Buy With $14 Price Target -March 04, 2025 at 07:10 am EST - Marketscreener.com
BTIG initiates Ardelyx with a Buy, sees attractive entry point after pullback - TipRanks
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Shareholders That Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class ActionARDX - ACCESS Newswire
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - ACCESS Newswire
Los Angeles Capital Management LLC Has $2.38 Million Stock Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying Activity - MarketBeat
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Insider Buying: Ardelyx, Inc. (NASDAQ:ARDX) Director Buys 77,729 Shares of Stock - MarketBeat
Wedbush Estimates Ardelyx's FY2029 Earnings (NASDAQ:ARDX) - MarketBeat
FINAL ARDX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ardelyx, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
HC Wainwright Estimates Ardelyx FY2029 Earnings - MarketBeat
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) PT at $9.93 - MarketBeat
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx director David Mott buys $388,738 in common stock By Investing.com - Investing.com South Africa
Ardelyx director David Mott buys $388,738 in common stock - Investing.com
Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Ardelyx Shares Up 1.2% As China Approves Co's Kidney Disease Dru… -February 26, 2025 at 09:42 am EST - Marketscreener.com
Ardelyx Secures $5M Milestone After China Approves Tenapanor For CKD - Nasdaq
Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell - Marketscreener.com
Ardelyx secures China approval for kidney disease drug By Investing.com - Investing.com South Africa
Ardelyx secures China approval for kidney disease drug - Investing.com India
Tenapanor Approved in China for Hyperphosphatemia - The Manila Times
Tenapanor approved in China for hyperphosphatemia - PharmaLive
Can Ardelyx's Newly Approved Kidney Disease Drug Transform China's Million-Patient Market? - StockTitan
Ardelyx (NASDAQ:ARDX) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | President & CEO |
Mar 07 '25 |
Sale |
5.36 |
41,668 |
223,199 |
1,635,138 |
| MOTT DAVID M | Director |
Feb 24 '25 |
Buy |
5.00 |
77,729 |
388,738 |
2,015,494 |
| Williams Laura A | Chief Medical Officer |
Feb 20 '25 |
Sale |
5.62 |
4,941 |
27,783 |
303,804 |
| Renz Justin A | Chief Financial Officer |
Feb 20 '25 |
Sale |
5.62 |
5,171 |
29,077 |
285,968 |
| RAAB MICHAEL | President & CEO |
Feb 20 '25 |
Sale |
5.62 |
22,964 |
129,124 |
1,085,755 |
| GRAMMER ELIZABETH A | See Remarks |
Feb 20 '25 |
Sale |
5.62 |
4,291 |
24,128 |
181,043 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):